Prevention of migraine during prodrome with naratriptan
Prevention of migraine during prodrome with naratriptan
复制标题
DOI：
10.1046/j.1468-2982.2000.00030.x
复制
发表时间：
2000-03-01
期刊：
影响因子：
4.9
通讯作者：
Cady, R
中科院分区：
文献类型：
--
作者：
Luciani, R;Carter, D;Cady, R
目的探讨那拉曲普坦在偏头痛前驱症状中的作用。程序基线阶段：记录前驱症状、发作时间、患者知道头痛不可避免的时间、头痛发作时间及头痛严重程度。治疗阶段：患者在知道头痛不可避免时服用那拉曲普坦2.5 mg。患者记录前驱症状和发作时间，他们知道头痛是不可避免的时间，那拉曲普坦给药时间，任何头痛的发作时间和严重程度。患者接受三种丙戊酸钠治疗，间隔至少48小时。结果20例患者完成了这两个阶段。在基线期，报告了59例头痛，随后均为头痛。头痛的严重程度：5%轻度，51%中度，44%重度。在治疗阶段，报告了63例复发。其中，38/63例（60%）未出现头痛。在发生的头痛中，大多数发生在那拉曲普坦给药后2小时内，这表明如果在前驱症状早期服用那拉曲普坦，则在预防头痛方面更有效。25例头痛的严重程度：44%轻度，24%中度，32%重度。结论那拉曲普坦2.5mg对偏头痛有预防作用。如果出现头痛，严重程度似乎会降低。
Objective To determine the role of naratriptan in preventing migraine headache when administered during prodrome. Procedures Baseline phase: patients recorded prodrome symptoms and time of onset, time when patient knew that headache was inevitable, time of onset and severity of headache. Treatment phase: patients given naratriptan 2.5 mg to take at the time they knew headache was inevitable. Patients recorded prodrome symptoms and time of onset, time they knew headache was inevitable, time naratriptan administered, time of onset and severity of any headache. Patients treated three prodromes separated by at least 48 h. Findings Twenty patients completed both phases. During baseline phase, 59 prodromes were reported and all were followed by headache. Severity of headache: 5% mild, 51% moderate, 44% severe. During treatment phase, 63 prodromes were reported. Of these, 38/63 (60%) were not followed by headache. Among headaches that occurred, the majority occurred within 2 h of naratriptan administration, suggesting that naratriptan is more effective in preventing headache if taken early in prodrome. Severity of 25 headaches: 44% mild, 24% moderate, 32% severe. Conclusions Naratriptan 2.5 mg appears to prevent migraine headache when given early in prodrome. If headache occurs, severity appears to be reduced.